Mackenzie Financial
KYNB

Mackenzie Financial’s Kyntra Bio KYNB Stock Holding History

Mackenzie Financial’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,878
Closed -$290K – 1724
2024
Q4 		$290K Buy
21,878
+17,643
+417% +$164K ﹤0.01% 1401
2024
Q3 		$42.3K Buy
4,235
+2,282
+117% +$34.4K ﹤0.01% 1547
2024
Q2 		$43.6K Buy
1,953
+941
+93% +$29.1K ﹤0.01% 1499
2024
Q1 		$59.5K Sell
1,012
-958
-49% -$41.3K ﹤0.01% 1472
2023
Q4 		$43.6K Sell
1,970
-90
-4% -$1.36K ﹤0.01% 1452
2023
Q3 		$38.1K Buy
2,060
+1,091
+113% +$42.8K ﹤0.01% 1430
2023
Q2 		$67.8K Buy
+969
New +$401K ﹤0.01% 1434
2022
Q4 		– Sell
-1,589
Closed -$517K – 1488
2022
Q3 		$517K Buy
+1,589
New +$512K ﹤0.01% 924
2020
Q3 		– Sell
-292
Closed -$295K – 1007
2020
Q2 		$295K Buy
292
+16
+6% +$14.9K ﹤0.01% 873
2020
Q1 		$240K Buy
+276
New +$274K ﹤0.01% 949

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mackenzie Financial's KYNB Position: Q1 2025 in Review

Mackenzie Financial sold out of Kyntra Bio (KYNB) in Q1 2025, closing a stake of 21,878 shares — an estimated $290K sold.

Mackenzie Financial first reported a position in KYNB in Q1 2020 and held it in 10 quarters. The position peaked at $517K in Q3 2022. 54 funds tracked by Wall St. Rank hold KYNB as of Q1 2025.

  • Mackenzie Financial reported no remaining Kyntra Bio position as of Q1 2025 after selling out during the quarter.
  • Mackenzie Financial sold 21,878 Kyntra Bio shares in Q1 2025, an estimated $290K.
  • Mackenzie Financial first reported a position in Kyntra Bio in Q1 2020 and held it in 10 quarters.
  • Mackenzie Financial's Kyntra Bio position peaked at $517K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2025.

Based on Mackenzie Financial's 13F filing for Q1 2025, filed 7 May 2025.